A Phase I Study To Evaluate The Antitumor Activity And Safety Of DUKE-002-VRP(HUHER2-ECD+TM), An Alphaviral Vector Encoding The HER2 Extracellular Domain And Transmembrane Region, In Patient With Locally Advanced Or Metastatic Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Cancers Including Breast Cancer
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 29 Mar 2017
At a glance
- Drugs AVX 901 (Primary)
- Indications Advanced breast cancer; Cancer; Gastric cancer
- Focus Adverse reactions
- 15 Feb 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 19 Apr 2015 Planned End Date changed from 1 Mar 2016 to 1 Dec 2017 as reported by ClinicalTrials.gov.